Experimental Pill Doubles Survival Time in Advanced Pancreatic Cancer Trial
Similar Articles
Pancreatic Cancer Survival Advances Through New Drugs and Vaccines
Scientists Develop Drug Method to Boost Natural Killer Cells Against Multiple Cancers
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
Common Asthma Drug Shows Promise Against Multiple Cancer Types in Early Research
A new oral drug called daraxonrasib significantly extended survival for patients with advanced pancreatic cancer in a major clinical trial. Patients taking the pill lived a median of 13.2 months, nearly double the 6.7 months for those on standard chemotherapy, while also reporting a better quality of life. The U.S. Food and Drug Administration (FDA) plans to expedite its review of the drug and has already allowed expanded access for some patients.
Facts First
- Daraxonrasib doubled median survival to 13.2 months compared to 6.7 months for chemotherapy.
- The drug targets a mutated KRAS protein that drives over 90% of pancreatic cancers, using a 'molecular glue' to bind to it.
- Patients reported less pain and a better quality of life with fewer severe side effects than the chemotherapy group.
- The FDA is expediting its review and has granted 'expanded access' for eligible patients while the process continues.
- The findings were published in the New England Journal of Medicine and presented at a major oncology conference.
What Happened
Researchers reported that the experimental drug daraxonrasib helped people with advanced pancreatic cancer live longer. In a study of 500 patients whose metastatic cancer had stopped responding to prior treatment, those randomly assigned to take the pill lived a median of 13.2 months, compared to a median of 6.7 months for those receiving more chemotherapy. The daraxonrasib group also reported fewer severe side effects, less pain, and a better quality of life as their tumors shrank. The study was funded by Revolution Medicines, the drug's developer, and its findings were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) meeting.
Why this Matters to You
Pancreatic cancer is one of the deadliest major cancers, with a five-year survival rate of just 13% and an estimated 67,000 new U.S. cases this year. This development may offer a new, more effective treatment option for patients who have run out of alternatives. If you or a loved one faces this diagnosis, the FDA's expedited review and expanded access program could make this therapy available sooner. The pill form and reported improvements in quality of life suggest a treatment that may be easier to tolerate than intensive chemotherapy.
What's Next
The FDA plans to expedite its review of daraxonrasib, a process that will determine whether the drug receives full approval for widespread use. In the interim, the agency is allowing 'expanded access' to the experimental drug for patients who meet certain criteria. Other drugs targeting specific KRAS subtypes and vaccine-based approaches to prevent recurrence after surgery are also in development, which could lead to a broader arsenal against this challenging disease.